Restoring Insulin Secretion (RISE): Design of studies of β-Cell preservation in prediabetes and early Type 2 diabetes across the life span

Diabetes Care

Volumn 37, Issue 3, 2014, Pages 780-788

  Edelstein, Sharon L ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; C PEPTIDE; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; INSULIN; INSULIN GLARGINE; LIRAGLUTIDE; METFORMIN; ANTIDIABETIC AGENT; GLUCAGON LIKE PEPTIDE 1; GLUCOSE BLOOD LEVEL;

ADULT; ARTICLE; BLOOD LEVEL; BODY MASS; CHILD; CLINICAL PROTOCOL; CONTROLLED STUDY; DIET RESTRICTION; DISEASE ASSOCIATION; DISEASE DURATION; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG RESPONSE; GLUCOSE TOLERANCE TEST; HUMAN; HUMAN CELL; HYPERGLYCEMIA; IMPAIRED GLUCOSE TOLERANCE; INSULIN RELEASE; INSULIN RESPONSE; LIFESPAN; MOLECULAR DYNAMICS; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; OUTCOME ASSESSMENT; PANCREAS ISLET BETA CELL; PANCREAS ISLET BETA CELL PRESERVATION; PANCREAS ISLET CELL FUNCTION; PRESERVATION; PROTEIN SECRETION; SCHOOL CHILD; ADOLESCENT; AGED; ANALOGS AND DERIVATIVES; BLOOD; CLINICAL TRIAL; COMPARATIVE STUDY; DIABETES MELLITUS, TYPE 2; DRUG COMBINATION; FEMALE; GASTROPLASTY; GLUCOSE BLOOD LEVEL; GLUCOSE CLAMP TECHNIQUE; INSULIN RESISTANCE; MALE; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; PHYSIOLOGY; PREDIABETIC STATE; PROCEDURES; RANDOMIZED CONTROLLED TRIAL; SECRETION (PROCESS); YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ARGININE; BLOOD GLUCOSE; C-PEPTIDE; CHILD; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; FEMALE; GASTROPLASTY; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE CLAMP TECHNIQUE; GLUCOSE TOLERANCE TEST; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN RESISTANCE; INSULIN-SECRETING CELLS; LIRAGLUTIDE; MALE; METFORMIN; MIDDLE AGED; PREDIABETIC STATE; YOUNG ADULT;

EID: 84896721972     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc13-1879     Document Type: Article

References (41)

1. Centers for Disease Control and Prevention. National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States, 2011 [internet], 2011. Atlanta, GA, U.S. Department of Health and Human Services, Centers for Disease Control and Prevention. Available from http://www.cdc.gov/diabetes/pubs/pdf/ndfs-2011. pdf. Accessed 13 February 2011
2. Kitabchi AE, TemprosaM, KnowlerWC, et al.; Diabetes Prevention Program Research Group. Role of insulin secretion and sensitivity in the evolution of type 2 diabetes in the Diabetes Prevention Program: effects of lifestyle intervention and metformin. Diabetes 2005;54: 2404-2414
3. Kahn SE, Lachin JM, Zinman B, et al.; ADOPT Study Group. Effects of rosiglitazone, glyburide, and metformin on b-cell function and insulin sensitivity in ADOPT. Diabetes 2011;60:1552-1560
4. Xiang AH, Peters RK, Kjos SL, Marroquin A, Goico J, Ochoa C, et al. Effect of pioglitazone on pancreatic b-cell function and diabetes risk in Hispanic women with prior gestational diabetes. Diabetes 2006; 55:517-522
5. Bacha F, Lee S, Gungor N, Arslanian SA. From pre-diabetes to type 2 diabetes in obese youth: pathophysiological characteristics along the spectrum of glucose dysregulation. Diabetes Care 2010; 33:2225-2231
6. Giannini C, Weiss R, Cali A, Bonadonna R, Santoro N, Pierpont B, et al. Evidence for early defects in insulin sensitivity and secretion before the onset of glucose dysregulation in obese youths: a longitudinal study. Diabetes 2012;61:606-614
7. Poitout V, Robertson RP. Glucolipotoxicity: fuel excess and b-cell dysfunction. Endocr Rev 2008;29:351-366
8. Buchanan TA, Xiang AH, Peters RK, et al. Preservation of pancreatic b-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women. Diabetes 2002;51:2796-2803
9. Knowler WC, Barrett-Connor E, Fowler SE, et al.; Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403
10. Salinari S, Bertuzzi A, Iaconelli A, Manco M, Mingrone G. Twenty-four hour insulin secretion and beta cell NEFA oxidation in type 2 diabetic, morbidly obese patients before and after bariatric surgery. Diabetologia 2008;51:1276-1284
11. Bradley D, Magkos F, Klein S. Effects of bariatric surgery on glucose homeostasis and type 2 diabetes. Gastroenterology 2012;143:897-912
12. Dixon JB, O'Brien PE, Playfair J, et al. Adjustable gastric banding and conventional therapy for type 2 diabetes: a randomized controlled trial. JAMA 2008; 299:316-323
13. Fehse F, Trautmann M, Holst JJ, et al. Exenatide augments first-and secondphase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab 2005;90: 5991-5997
14. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006;368:1696-1705
15. Knowler WC, Hamman RF, Edelstein SL, et al.; Diabetes Prevention Program Research Group. Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program. Diabetes 2005;54: 1150-1156
16. DeFronzo RA, Tripathy D, Schwenke DC, et al.; ACT NOW Study. Pioglitazone for diabetes prevention in impaired glucose tolerance. N Engl J Med 2011;364:1104-1115
17. Ramachandran A, Snehalatha C, Mary S, et al. Pioglitazone does not enhance the effectiveness of lifestyle modification in preventing conversion of impaired glucose tolerance to diabetes in Asian Indians: results of the Indian Diabetes Prevention Programme-2 (IDPP-2). Diabetologia 2009; 52:1019-1026
18. The ORIGIN Trial Investigators. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med. 2012;367:319-328
19. Kahn SE, Haffner SM, Heise MA, et al.; ADOPT Study Group. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006;355: 2427-2443
20. Lindblad U, Lindberg G, Mansson NO, et al. Can sulphonylurea addition to lifestyle changes help to delay diabetes development in subjects with impaired fasting glucose? The Nepi ANtidiabetes StudY (NANSY). Diabetes ObesMetab 2011; 13:185-188
21. Sartor G, Schersten B, Carlstrom S, Melander A, Norden A, Persson G. Ten-year follow-up of subjects with impaired glucose tolerance: prevention of diabetes by tolbutamide and diet regulation. Diabetes 1980;29:41-49
22. Holman RR, Haffner SM, McMurray JJ, et al.; NAVIGATOR Study Group. Effect of nateglinide on the incidence of diabetes and cardiovascular events. N Engl J Med 2010;362:1463-1476
23. Chiasson JL, Josse RG, Gomis R, HanefeldM, Karasik A, Laakso M; STOP-NIDDM Trial Research Group. Acarbose for prevention of type 2 diabetes mellitus: the STOPNIDDM randomised trial. Lancet 2002;359: 2072-2077
24. Kirkman MS, Shankar RR, Shankar S, et al. Treating postprandial hyperglycemia does not appear to delay progression of early type 2 diabetes: the Early Diabetes Intervention Program. Diabetes Care 2006; 29:2095-2101
25. Lindstrom J, Ilanne-Parikka P, Peltonen M, et al.; Finnish Diabetes Prevention Study Group. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study. Lancet 2006; 368:1673-1679
26. Carlsson LM, Peltonen M, Ahlin S, et al. Bariatric surgery and prevention of type 2 diabetes in Swedish obese subjects. N Engl J Med 2012;367:695-704
27. Tuomilehto J, Lindstrom J, Eriksson JG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001;344:1343-1350
28. Pan XR, Li GW, Hu YH, et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care 1997;20:537-544
29. Diabetes Prevention Program Research Group. Effects of withdrawal from metformin on the development of diabetes in the Diabetes Prevention Program. Diabetes Care 2003;26:977-980
30. Garvey WT, Olefsky JM, Griffin J, Hamman RF, Kolterman OG. The effect of insulin treatment on insulin secretion and insulin action in type II diabetes mellitus. Diabetes 1985;34:222-234
31. Weng J, Li Y, Xu W, et al. Effect of intensive insulin therapy on b-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial. Lancet 2008;371:1753-1760
32. The TODAY Study Group. A clinical trial to maintain glycemic control in youth with type 2 diabetes. N Engl J Med 2012;366: 2247-2256
33. The TODAY Study Group. Effects of metformin, metformin plus rosiglitazone, and metformin plus lifestyle on insulin sensitivity and b-cell function in TODAY. Diabetes Care 2013;36:1749-1757
34. Bunck MC, DiamantM, Corńer A, et al. Oneyear treatment with exenatide improves b-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial. Diabetes Care 2009;32:762-768
35. Bunck MC, Corńer A, Eliasson B, et al. Effects of exenatide on measures of b-cell function after 3 years in metformin-treated patients with type 2 diabetes. Diabetes Care 2011;34:2041-2047
36. Gregg EW, Chen H, Wagenknecht LE, et al. Association of an intensive lifestyle intervention with remission of type 2 diabetes. JAMA 2012;308:2489-2496
37. Dunning BE, Gerich JE. The role of alpha-cell dysregulation in fasting and postprandial hyperglycemia in type 2 diabetes and therapeutic implications. Endocr Rev 2007; 28:253-283
38. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007;356:2457-2471
39. Kahn SE, Zinman B, Lachin JM, Haffner SM, Herman WH, Holman RR, et al. Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT). Diabetes Care 2008;31:845-851
40. Bacha F, Pyle L, Nadeau K, et al.; TODAY Study group. Determinants of glycemic control in youth with type 2 diabetes at randomization in the TODAY study. Pediatr Diabetes 2012;13:376-383
41. Marcus R, Peritz E, Gabriel KR. On closed testing procedures with special reference to ordered analysis of variance. Biometrika 1976;63:655-660